NUZ
NEURIZON THERAPEUTICS LIMITED
$0.0590
0.00%
Market cap
$47M
Turnover
$79,898
Last price
$0.0590
Day change
0.00%
Announcements
19
Range, past year
Open 0.115 · Low 0.053 · Now 0.059 · High 0.185
Open NUZ in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
NUZ momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
28/100
Wyckoff phase
Downtrend11d
Trend stage
Breakdown
1 Day
+0.0%
1 Week
-1.7%
1 Month
-27.2%
1 Year
-46.4%
RSI
33
Avg daily range
8.7%
NEURIZON THERAPEUTICS LIMITED scores 28 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 11 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -39.1%
- High volatility (ATR 8.7%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsNUZ announcements
Recent price-sensitive releases.
- 2026-11-16 Share Purchase Plan and Options Offer Open Placement | Security Purchase Plan
- 2026-11-13 First Regimen I patient enters Active Treatment Extension Progress Report
- 2026-10-29 Trading Halt Trading Halt
- 2026-10-28 Appendix 4C & Quarterly Update Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-10-06 FDA Type C Feedback, HEALEY trial potentially registrational Progress Report
- 2026-09-10 Neurizon Announces Partial Redemption of Convertible Notes Issued Capital - Other
- 2026-09-09 NIH funds Expanded Access Program for NUZ-001 in ALS Progress Report
More Health Care stocks
Most traded in the same sector.